Company intelligence / Profile preview

ORIC Pharmaceuticals

South San Francisco, California, United Statesoricpharma.com ↗

Ownership: Public · ORIC
Employees: ~75
Development stage: Phase 1

Overview

As of early 2025, ORIC has three main programs in phase 1 trials. ORIC‑533 showed initial promise but failed in trials. The lead assets are now ORIC‑114—demonstrating strong CNS penetration and promising results for brain metastasized NSCLC—and ORIC‑944 for prostate cancer, which has shown encouraging efficacy signals and attracted pharma interest. All programs remain high-risk as they are still early-stage; more mature data will be needed to confirm efficacy.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

rinzimetostat

4 more assets in the full pipeline.

Request access →

Partnerships

Clinical collaborations supporting ongoing trial evaluating ORIC‑944 in combination with AR inhibitors for prostate cancer; specific partners not named publicly as of current disclosures

Financials

Market cap: $1.3B
Total revenue: $0
Enterprise value: $1B

Beyond the preview

Go deeper on ORIC Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIC Pharmaceuticals.

Explore the full profile